The aim of this case report was to describe a potential anti-interleukin (IL)-6 treatment for cryptogenic new-onset refractory status epilepticus (C-NORSE). Background: Although an underlying immune-mediated pathogenesis is considered present in some C-NORSE cases, many cases do not respond to classical immunotherapies. Case report: We describe the case of a 46-year-old woman with C-NORSE who achieved cessation of long-lasting status epilepticus following administration of tocilizumab, an IL-6 receptor-blocking antibody, although the final outcome was poor. Conclusions: Anti-IL-6 treatment may prove effective in stopping status epilepticus in some C-NORSE cases.

The first course of chemotherapy was administered with dexamethasone and lenalidomide. Although it decreased the serum κ free light chains level and the ratio of κ to λ, the muscle strength gradually reduced, and he experienced aspiration pneumonia several times. Although he was transferred for palliative treatment, he died of aspiration pneumonia.

A case of brain and spinal cord infarction caused by artery-to-artery embolism from the aberrant right subclavian artery stenosis